Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002311 · ClinicalTrials.gov registry record · NA
Improving Follow-Up for Discharged Emergency Care Patients
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 327
- Enrollment target
NCT03002311: Completed NA study, sponsored by Washington University School of Medicine.
NCT03002311 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 327 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002311, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 327 participants
- Enrollment target
Study Summary
This study's purpose is to test the effects of an electronic health intervention platform developed by Epharmix (also known as CareSignal), which features two-way SMS text messages and phone calls intended to improve clinical outcomes compared to the standard of care. This was a randomized open, blinded end-point (PROBE) trial of adult patients discharged from the ED and referred to a provider for follow-up care. Participants in the intervention arm received a self-scheduling text or phone message that automatically connected them to their referral provider to schedule a follow-up appointment and sent them appointment reminders. Those in the control arm received standard of care written instructions to contact listed referral providers. The primary outcome was time to the follow-up appointment.
Primary Outcome
The primary outcome was the effect of the intervention on time to follow-up appointment using an intention-to-treat analysis and plotting the cumulative incidence functions (CIFs). Follow-up adherence was defined as a recorded visit in the EMR to the referral primary or specialty care provider within 120 days after ED discharge to address a similar diagnosis (or complaint) at the index ED visit.
Interventions
- DEVICE Epharmix/CareSignal eHealth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2018-03-09 |
| Phase | NA |
What the finished NCT03002311 record still lists
NCT03002311 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Epharmix/CareSignal eHealth is the first listed.
NCT03002311 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03002311 about?
NCT03002311 is a clinical study titled "Improving Follow-Up for Discharged Emergency Care Patients". This study's purpose is to test the effects of an electronic health intervention platform developed by Epharmix (also known as CareSignal), which features two-way SMS text messages and phone calls intended to improve clinical outcomes compared to the standard of care. This was a randomized open, bli...
What is the current status of trial NCT03002311?
This trial is currently completed. It is a NA study. The enrollment target is 327 participants. The study started on 2016-01-01. Estimated completion is 2018-03-09.
What interventions are being tested in trial NCT03002311?
The interventions under investigation include: Epharmix/CareSignal eHealth (DEVICE).
Who is sponsoring clinical trial NCT03002311?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03002311's enrollment target sits among peer trials
327 309th of 2000 higher than 1,691 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI